Immunogenicity and safety of concomitant vaccines given with 20-valent pneumococcal conjugate vaccine in healthy infants
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The 20-valent pneumococcal conjugate vaccine (PCV20) demonstrated non-inferior immunogenicity and similar safety when co-administered with routine pediatric vaccines compared to the 13-valent PCV (PCV13). This supports the safe use of PCV20 in infant immunization schedules.
Area Of Science
- Immunology
- Vaccinology
- Pediatric Medicine
Background
- Pneumococcal conjugate vaccines (PCVs) are crucial for infant immunization and often administered alongside other routine pediatric vaccines.
- Evaluating the safety and immunogenicity of new vaccine formulations in combination with existing schedules is essential for public health.
Purpose Of The Study
- To assess the safety and immunogenicity of the 20-valent pneumococcal conjugate vaccine (PCV20) when given concurrently with other recommended pediatric vaccines.
- To demonstrate non-inferior immune responses to routine vaccines when administered with PCV20 compared to the 13-valent PCV (PCV13).
Main Methods
- Two Phase 3, double-blind, randomized trials (N=1997 and N=1207) evaluated PCV20 in infant schedules with combination vaccines (diphtheria, tetanus, acellular pertussis [DTaP]-hepatitis B-poliovirus [HBV]-Haemophilus influenzae type b [Hib]) and MMR/varicella vaccines.
- Immunogenicity was assessed by measuring antibody levels to routine vaccine antigens post-vaccination, comparing PCV20 to PCV13.
- Safety endpoints included systemic events and adverse events (AEs).
Main Results
- Non-inferiority of immune responses was met for DTaP-HBV-IPV, Hib, MMR, and varicella vaccines when co-administered with PCV20 compared to PCV13.
- Frequencies of systemic events and adverse events were similar between the PCV20 and PCV13 groups, with most events being mild to moderate in severity.
Conclusions
- The 20-valent pneumococcal conjugate vaccine (PCV20) can be safely administered with routine pediatric vaccines.
- Co-administration of PCV20 with other pediatric vaccines results in comparable immunogenicity to co-administration with PCV13, supporting its integration into infant immunization programs.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Overview
Vaccination is the administration of antigenic material from pathogens to confer immunity against a specific microorganism. Vaccination primes the immune system to recognize and mount an immune response faster and more effectively if the real pathogen is encountered. Vaccinations are one of the most efficient ways to protect both individual humans and the general public from disease. A growing anti-vaccination skepticism risks the successes of vaccination programs that helped reduce...
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...